Literature DB >> 16006881

Use of extended pattern technique for initial prostate biopsy.

Wendy Siu1, Rodney L Dunn, Rajal B Shah, John T Wei.   

Abstract

PURPOSE: An extended prostate biopsy schema has been advocated at initial prostate biopsy to decrease the rate of false-negative cancer cases. However, critics have raised concerns that this may lead to the greater detection of clinically insignificant cancers. We examined the impact of using an extended pattern schema on cancer detection and also on the finding of smaller and clinically insignificant cancer.
MATERIALS AND METHODS: Clinical data, including patient age, race, prebiopsy prostate specific antigen (PSA), digital rectal examination, prostate volume, number of needle cores and biopsy findings were abstracted from the medical records of all patients who underwent prostate biopsy in a 5-year period. Extended pattern prostate biopsy was defined as more than 10 cores. Clinically insignificant cancer was defined as a maximal tumor dimension of 1.0 cm or less, Gleason sum 6 or less and organ confined disease at radical prostatectomy. Adjusted regression models were developed to assess the independent effects of using an extended biopsy pattern on the detection of cancer overall and on the detection of clinically insignificant cancer.
RESULTS: A total of 740 men with a mean age of 62.6 years were referred for prostate biopsy. Median PSA was 5.7 ng/ml and prostate volume was 39.7 cc. The OR for detecting prostate cancer was 1.55 (95% CI 1.09 to 2.19) for the extended pattern compared with standard biopsy. Of the subset of 136 patients who underwent radical prostatectomy 12.6% had clinically insignificant cancer. However, in contrast to overall cancer detection, extended pattern prostate biopsy was not found to be associated with an increased risk of detecting smaller or clinically insignificant cancer. PSA density was the single parameter found to be independently associated with the detection of clinically insignificant cancer (95% CI 0.20 to 0.98).
CONCLUSIONS: Using an extended prostate biopsy pattern involving more than 10 cores increases the likelihood of detecting prostate cancer. A significant association between more needle cores at initial prostate biopsy and finding smaller and clinically insignificant cancer was not apparent.

Entities:  

Mesh:

Year:  2005        PMID: 16006881     DOI: 10.1097/01.ju.0000165385.53652.7a

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  16 in total

1.  Using biopsy to detect prostate cancer.

Authors:  Shahrokh F Shariat; Claus G Roehrborn
Journal:  Rev Urol       Date:  2008

2.  Prostate capsule sparing versus nerve sparing radical cystectomy for bladder cancer: results of a randomized, controlled trial.

Authors:  Bruce L Jacobs; Stephanie Daignault; Cheryl T Lee; Khaled S Hafez; Jeffrey S Montgomery; James E Montie; Jean E Humrich; Brent K Hollenbeck; David P Wood; Alon Z Weizer
Journal:  J Urol       Date:  2014-07-24       Impact factor: 7.450

Review 3.  Standards for prostate biopsy.

Authors:  Marc A Bjurlin; Samir S Taneja
Journal:  Curr Opin Urol       Date:  2014-03       Impact factor: 2.309

Review 4.  Optimization of prostate biopsy: the role of magnetic resonance imaging targeted biopsy in detection, localization and risk assessment.

Authors:  Marc A Bjurlin; Xiaosong Meng; Julien Le Nobin; James S Wysock; Herbert Lepor; Andrew B Rosenkrantz; Samir S Taneja
Journal:  J Urol       Date:  2014-04-21       Impact factor: 7.450

5.  Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA.

Authors:  Scott A Tomlins; Sheila M J Aubin; Javed Siddiqui; Robert J Lonigro; Laurie Sefton-Miller; Siobhan Miick; Sarah Williamsen; Petrea Hodge; Jessica Meinke; Amy Blase; Yvonne Penabella; John R Day; Radhika Varambally; Bo Han; David Wood; Lei Wang; Martin G Sanda; Mark A Rubin; Daniel R Rhodes; Brent Hollenbeck; Kyoko Sakamoto; Jonathan L Silberstein; Yves Fradet; James B Amberson; Stephanie Meyers; Nallasivam Palanisamy; Harry Rittenhouse; John T Wei; Jack Groskopf; Arul M Chinnaiyan
Journal:  Sci Transl Med       Date:  2011-08-03       Impact factor: 17.956

Review 6.  [Fusion imaging in urology: combination of MRI and TRUS for detection of prostate cancer].

Authors:  D Schilling; M Kurosch; R Mager; I Tsaur; A Haferkamp; M Röthke
Journal:  Urologe A       Date:  2013-04       Impact factor: 0.639

7.  CCL11 (eotaxin-1): a new diagnostic serum marker for prostate cancer.

Authors:  Manisha Agarwal; Chang He; Javed Siddiqui; John T Wei; Jill A Macoska
Journal:  Prostate       Date:  2012-10-11       Impact factor: 4.104

8.  The 20-core prostate biopsy as an initial strategy: impact on the detection of prostatic cancer.

Authors:  Mohamed Amine Jradi; Mohamed Dridi; Mourad Teyeb; Mokhtar Ould Sidi Mohamed; Ramzi Khiary; Samir Ghozzi; Nawfel Ben Rais
Journal:  Can Urol Assoc J       Date:  2010-04       Impact factor: 1.862

9.  Limitations of a contemporary prostate biopsy: the blind march forward.

Authors:  John T Wei
Journal:  Urol Oncol       Date:  2010 Sep-Oct       Impact factor: 3.498

Review 10.  Random biopsy: when, how many and where to take the cores?

Authors:  Vincenzo Scattoni; Carmen Maccagnano; Umberto Capitanio; Andrea Gallina; Alberto Briganti; Francesco Montorsi
Journal:  World J Urol       Date:  2014-06-08       Impact factor: 4.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.